Quantcast

Latest lung cancer Stories

2014-04-29 16:32:08

- Zykadia (ceritinib) demonstrated an overall response rate of 54.6% in patients with ALK+ metastatic NSCLC who have no other treatment option[1] EAST HANOVER, N.J., April 29, 2014 /PRNewswire/ -- Novartis announced today that the US Food and Drug Administration (FDA) has approved Zykadia(TM) (ceritinib, previously known as LDK378) for the treatment of patients with anaplastic lymphoma kinase-positive (ALK+) metastatic non-small cell lung cancer (NSCLC) who have progressed on or are...

2014-04-29 16:31:09

Polaris Group Scientific Colleagues from Several University Cancer Centers Present Data at 2014 AACR Meeting in San Diego, CA SAN DIEGO, April 29, 2014 /PRNewswire/ -- Polaris Group collaborating scientists from numerous institutions reported results from preclinical studies at the 2014 annual American Association for Cancer Research (AACR) meeting, which showed that certain non-small cell lung cancers (NSCLC), malignant pleural mesothelioma (MPM) and melanomas are more likely to...

2014-04-29 12:27:59

Improvements in Key Efficacy Endpoints, Especially Overall Survival, are Pivotal Drivers for Prescribing, According to a New Report from Decision Resources Group BURLINGTON, Mass., April 29, 2014 /PRNewswire/ -- Decision Resources Group finds that interviewed oncologists' are optimistic that Boehringer Ingelheim's second-generation irreversible EGFR tyrosine kinase inhibitor (TKI) Gilotrif/Giotrif will offer efficacy and delivery advantages over currently available agents for the second- and...

2014-04-28 08:26:37

LONDON, April 28, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014http://www.reportbuyer.com/pharma_healthcare/research_rd/clinical_trials/non_small_cell_lung_cancer_global_clinical_trials_review.html Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014SummaryGlobalData's clinical trial report, "Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014" provides data...

2014-04-25 08:27:52

NEW YORK, April 25, 2014 /PRNewswire/ -- Uniting Against Lung Cancer (UALC), a nonprofit dedicated to funding innovative research and raising awareness for lung cancer, announces that it has achieved a new level of funding this year, committing more than $1.5 million in lung cancer research grants to premier medical and research institutions across the country. This contribution brings UALC's total funding for lung cancer research grants to a total of $11.5 million. Lung cancer is...

2014-04-24 12:54:13

Rates for all other cancers, except female lung cancer, continue to fall Pancreatic cancer is the only cancer for which deaths are predicted to increase in men and women rather than decrease in 2014 and beyond, according to a comprehensive study published in the leading cancer journal Annals of Oncology today (Thursday). The study by researchers in Italy and Switzerland shows that the proportion of deaths due to any sort of cancer is expected to fall overall in Europe in 2014. There are...

2014-04-24 12:30:28

The Majority of Non-Prescribers Anticipate Prescribing Gilotrif Within the Next Three Months, According to Findings from Decision Resources Group BURLINGTON, Mass., April 24, 2014 /PRNewswire/ -- Decision Resources Group finds that at six months post-launch in the United States, 49 percent of surveyed U.S. medical oncologists have prescribed Boehringer Ingelheim's irreversible epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI) Gilotrif, for NSCLC patients outside of...

2014-04-23 23:08:57

For the fourth consecutive year, Austin-based Alen Corporation will have a significant presence at the American Lung Association’s (ALA) Fight for Air Climb, taking place April 26 at the Frost Bank Tower in downtown Austin, Texas. Alen, an air purifier company, says its involvement is just one way that it is working to bring awareness to the health issues associated with poor indoor air quality. Austin, TX (PRWEB) April 23, 2014 The Fight for Air Climb’s purpose is to call attention...

2014-04-19 23:00:42

ReportsnReports.com adds the latest report on “Non-Small Cell Lung Cancer Global Clinical Trials Review, H1, 2014” to its store. Order a copy of this report at http://www.reportsnreports.com/purchase.aspx?name=279869. Dallas, TX (PRWEB) April 19, 2014 This report provides data on the Non-Small Cell Lung Cancer clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Non-Small Cell Lung Cancer. It includes an overview of the trial...

2014-04-17 23:01:36

Zoll, Kranz & Borgess, LLC, (ZKB) a pharmaceutical and medical device litigation firm, is currently investigating claims of men who developed melanoma after taking the pharmaceutical drug, Viagra (sildenafil citrate), which is marketed by the US-based pharmaceutical company, Pfizer. Toledo, OH (PRWEB) April 17, 2014 Studies have suggested that sildenafil use may increase the invasiveness of melanoma cells, which may raise the possible adverse effect of melanoma. On April 7, 2014, a...


Latest lung cancer Reference Libraries

Clinical Lung Cancer
2012-05-14 11:09:55

Clinical Lung Cancer is a peer-reviewed medical journal published bimonthly by the CIG Media Group. It was established in 1999. As of May 2012, the editor-in-chief is David R. Gandara. Gandara is a member of the Board of Directors of the International Association for the Study of Lung Cancer and the Addario Foundation. He has also served as a member of the Board of Directors of the American Society of Clinical Oncology (ASCO) and as secretary-treasurer. He is furthermore a member of...

More Articles (1 articles) »
Word of the Day
grass-comber
  • A landsman who is making his first voyage at sea; a novice who enters naval service from rural life.
According to the OED, a grass-comber is also 'a sailor's term for one who has been a farm-labourer.'